» Articles » PMID: 18836152

Cognitive Impairment: an Increasingly Important Complication of Type 2 Diabetes: the Age, Gene/environment Susceptibility--Reykjavik Study

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 2008 Oct 7
PMID 18836152
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Persons with type 2 diabetes are at increased risk of cognitive dysfunction. Less is known about which cognitive abilities are affected and how undiagnosed diabetes and impaired fasting glucose relate to cognitive performance. The authors explored this question using data from 1,917 nondemented men and women (average age = 76 years) in the population-based Age, Gene/Environment Susceptibility-Reykjavik Study (2002-2006). Glycemic status groups included diagnosed diabetes (self-reported diabetes or diabetic medication use; n = 163 (8.5%)), undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed diabetes; n = 55 (2.9%)), and impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744 (38.8%)). Composites of memory, processing speed (PS), and executive function were constructed from a neuropsychological battery. Linear regression was used to investigate cross-sectional differences in cognitive performance between glycemic groups, adjusted for demographic and health factors. Persons with diagnosed diabetes had slower PS than normoglycemics (beta = -0.12; P < 0.05); diabetes duration of >or=15 years was associated with significantly poorer PS and executive function. Undiagnosed diabetics had slower PS (beta = -0.22; P < 0.01) and poorer memory performance (beta = -0.22; P < 0.05). Persons with type 2 diabetes have poorer cognitive performance than normoglycemics, particularly in PS. Those with undiagnosed diabetes have the lowest cognitive performance.

Citing Articles

Dietary approach to stop hypertension (DASH), but not Mediterranean and MIND, dietary pattern protects against Parkinson's disease.

Keramati M, Kheirouri S, Etemadifar M Food Sci Nutr. 2024; 12(2):943-951.

PMID: 38370088 PMC: 10867496. DOI: 10.1002/fsn3.3809.


Tau Loss of Function, by Deletion or Aggregation, Contributes to Peripheral Insulin Resistance.

Al-Lahham R, Mendez N J Alzheimers Dis. 2023; 95(3):1041-1058.

PMID: 37638441 PMC: 10578286. DOI: 10.3233/JAD-230392.


Exposure factors associated with dementia among older adults in Iceland: the AGES-Reykjavik study.

Valsdottir V, Magnusdottir B, Gylfason H, Chang M, Aspelund T, Gudnason V Geroscience. 2023; 45(3):1953-1965.

PMID: 37160657 PMC: 10400491. DOI: 10.1007/s11357-023-00804-7.


A population-based meta-analysis of circulating GFAP for cognition and dementia risk.

Gonzales M, Wiedner C, Wang C, Liu Q, Bis J, Li Z Ann Clin Transl Neurol. 2022; 9(10):1574-1585.

PMID: 36056631 PMC: 9539381. DOI: 10.1002/acn3.51652.


The association between undiagnosed diabetes and cognitive function: findings from the China health and retirement longitudinal study.

Yang J, Xu H, Li J, Zhao Y, Guan S, Fu Y BMC Endocr Disord. 2022; 22(1):151.

PMID: 35658946 PMC: 9167534. DOI: 10.1186/s12902-022-01055-x.


References
1.
Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

2.
Fontbonne A, Berr C, Ducimetiere P, Alperovitch A . Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001; 24(2):366-70. DOI: 10.2337/diacare.24.2.366. View

3.
Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350(14):1387-97. DOI: 10.1056/NEJMoa032804. View

4.
den Heijer T, Vermeer S, van Dijk E, Prins N, Koudstaal P, Hofman A . Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003; 46(12):1604-10. DOI: 10.1007/s00125-003-1235-0. View

5.
Klein J, Waxman S . The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet Neurol. 2003; 2(9):548-54. DOI: 10.1016/s1474-4422(03)00503-9. View